A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin and/or SGLT2 Inhibitor
Latest Information Update: 27 Jun 2025
At a glance
- Drugs Retatrutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms TRANSCEND-T2D-3
- Sponsors Eli Lilly and Company
Most Recent Events
- 06 Dec 2024 Planned End Date changed from 9 Oct 2026 to 1 Oct 2026.
- 06 Dec 2024 Planned primary completion date changed from 11 Sep 2026 to 1 Sep 2026.
- 10 Apr 2024 Status changed from not yet recruiting to recruiting.